Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Malignancy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43865   clinical trials with a EudraCT protocol, of which   7286   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,202 result(s) found for: Malignancy. Displaying page 1 of 61.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2009-009756-21 Sponsor Protocol Number: 20070315 Start Date*: 2009-10-26
    Sponsor Name:Amgen Inc
    Full Title: A Single-arm, Multicenter, Proof-of-concept Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects with Elevated Serum Calcium Despite Recent Treatment with IV Bisphosphonates.
    Medical condition: Hypercalcemia of malignancy (HCM)
    Disease: Version SOC Term Classification Code Term Level
    15.0 10014698 - Endocrine disorders 10020588 Hypercalcemia of malignancy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-012300-69 Sponsor Protocol Number: Number 1 Start Date*: 2010-03-26
    Sponsor Name:Meander Medisch Centrum
    Full Title: Does vitamin D deficiency contribute to fatigue in patients in remission after treatment of gynaecological malignancy?
    Medical condition: Vitamin D deficiency in patients in complete remission after successful treatment of a gynaecological malignancy.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-007652-34 Sponsor Protocol Number: Bismuth-PBH-2008 Start Date*: 2009-03-05
    Sponsor Name:Herlev Hospital, Dept. of haematology (L121)
    Full Title: Kan mineraltilskud med bismuth mindske toksiciteten af kemoterapi og strålebehandling? En klinisk prospektiv, dobbeltblind randomiseret undersøgelse af patienter med hæmatologiske sygdomme som modt...
    Medical condition: Malignant diseases of the blood requiring chemotherapy and/or radiation therapy of head and neck
    Disease: Version SOC Term Classification Code Term Level
    9.1 10066481 Hematological malignancy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-004535-72 Sponsor Protocol Number: TEIC_HM_1 Start Date*: 2014-01-17
    Sponsor Name:Tallaght Hospital, Dublin 24, Ireland
    Full Title: A prospective, single-centre, cohort study to determine the pharmacokinetic and pharmacodynamic parameters of teicoplanin in adult patients with haematological malignancy.
    Medical condition: Suspected or confirmed Gram-positive infection in patients with haematological malignancy.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-003310-24 Sponsor Protocol Number: UDCAPSCSURV Start Date*: 2015-10-09
    Sponsor Name:Sahlgrenska Academy
    Full Title: A Phase 3, Open-label, Randomized, Prospective Clinical Trial Evaluating the Efficacy of Stratified Treatment with Ursodeoxycholic Acid (UDCA) in Preventing Hepatobiliary and Colorectal Malignancy ...
    Medical condition: Primary sclerosing cholangitis with or without concomitant inflammatory bowel disease included in an unlimited surveillance program for hepatobiliary and colorectal malignancy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-004764-30 Sponsor Protocol Number: BRD11/6-N Start Date*: Information not available in EudraCT
    Sponsor Name:CHU Nantes
    Full Title: Phase 2 study of a reduced-toxicity myeloablative conditionning regimen using fludarabine and full doses of IV busulfan in pediatric patients not eligible for standard myeloablative conditioning r...
    Medical condition: Hematological malignancy
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066481 Hematological malignancy LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-002053-31 Sponsor Protocol Number: ALEC4005 Start Date*: 2005-08-16
    Sponsor Name:Hammersmith Hospital
    Full Title: To determine the diagnostic accuracy of MRI in detecting lymph node metastases using USPIO (Ultra small super-paramagnetic iron oxide particles) in patients with gynecological malignancy
    Medical condition: Gynaecological malignancies
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-001107-33 Sponsor Protocol Number: NL76863.068.21 Start Date*: 2021-03-10
    Sponsor Name:MUMC
    Full Title: SARS-CoV-2 vaccination response in patients with haematological disease
    Medical condition: multiple myeloma chronic lymphocytic leukemia, non-Hodgkin lymphoma,
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10066481 Hematological malignancy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-001642-18 Sponsor Protocol Number: D8230C00002 Start Date*: 2021-05-13
    Sponsor Name:AstraZeneca AB
    Full Title: A Modular Phase I/II, Open-label, Multicentre Study to Assess AZD4573 in Novel Combinations with Anti-cancer Agents in Patients with Advanced Haematological Malignancies
    Medical condition: Haematological Malignancies
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066476 Haematological malignancy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Temporarily Halted) ES (Temporarily Halted) FR (Completed) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-004369-16 Sponsor Protocol Number: MJ/LPGB/12/2006 Start Date*: 2007-11-29
    Sponsor Name:St Raphael's Hospice, Surrey
    Full Title: ''Evaluation of the efficacy of 'TRANS-DERMAL NITRATE' in reducing the severity of 'death-rattle' (i.e 'terminal lung secretions' ) in patients dying from end stage malignancy''
    Medical condition: 'Death-rattle' (i.e 'terminal lung secretions') in adult patients dying from end-stage malignancy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2010-021221-12 Sponsor Protocol Number: UMC Utrecht Start Date*: 2011-07-11
    Sponsor Name:UMCU
    Full Title: A phase I/ II study Efficacy and safety of alpha/beta T- /CD19B-cell depleted allogeneic haematopoietic stem cells transplantation in high risk or relapsed acute leukaemia / MDS followed by an inn...
    Medical condition: Patients with high risk acute leukemia / MDS or relapse acute leukemia /MDS
    Disease: Version SOC Term Classification Code Term Level
    12.1 10066481 Hematological malignancy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-005766-39 Sponsor Protocol Number: GS-US-313-2120 Start Date*: 2016-04-26
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: An Open Label, Roll Over Study to Provide Idelalisib to Subjects Previously Treated with the Investigational PI3Kδ Inhibitor, GS-9820
    Medical condition: Lymphoid Malignancies
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10066481 Hematological malignancy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2008-006175-75 Sponsor Protocol Number: BRD 08/9-P Start Date*: 2008-12-24
    Sponsor Name:CHU de Nantes
    Full Title: ETUDE DE PHASE II D’UN CONDITIONNEMENT SUB-MYELOABLATIF A TOXICITE REDUITE AVANT ALLOGREFFE DE CELLULES SOUCHES HEMATOPOÏETIQUES DANS LE TRAITEMENT DES HEMOPATHIES MALIGNES
    Medical condition: Hémopathies malignes
    Disease: Version SOC Term Classification Code Term Level
    9.1 10066476 Haematological malignancy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-001080-27 Sponsor Protocol Number: CD45RADLIHaplo Start Date*: 2022-11-23
    Sponsor Name:University Hospital Tuebingen
    Full Title: A multi-center phase I/II trial of memory T cell donor lymphocyte infusions after transplantation of CliniMACS TCRα/β and CD19 depleted stem cell grafts from haploidentical donors for hematopoietic...
    Medical condition: Patients suffering from hematological malignancies and eligible for haploidentical allogeneic stem cell transplantation. Patients will be included prior start of conditioning for SCT. Inclusion cri...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066481 Hematological malignancy LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2016-001860-12 Sponsor Protocol Number: CMAK683X2101 Start Date*: 2017-01-26
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase I/II, multicenter, open-label study of MAK683 in adult patients with advanced malignancies
    Medical condition: Advanced malignancies
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065252 Solid tumor LLT
    21.1 100000004864 10066481 Hematological malignancy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Ongoing) ES (Prematurely Ended) IT (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2013-001418-13 Sponsor Protocol Number: TED10893 Start Date*: 2014-11-04
    Sponsor Name:Sanofi-aventis recherche & développement
    Full Title: A Phase I Dose Escalation Safety and Pharmacokinetic Study of Multiple Intravenous Administrations of a Humanized Monoclonal Antibody (SAR650984) Against CD38 In Patients with Selected CD38+ Hemat...
    Medical condition: Haematological malignancy
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066476 Haematological malignancy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) GR (Completed) GB (GB - no longer in EU/EEA) FI (Completed) BE (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-001700-15 Sponsor Protocol Number: MK-7684A-004 Start Date*: 2021-10-14
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 2, Open-label Study to Evaluate the Safety and Efficacy of MK-7684A (MK-7684 [Vibostolimab] with MK-3475 [Pembrolizumab] Coformulation) in Participants with Relapsed or Refractory Hematolog...
    Medical condition: Relapsed/refractory hematological malignancies
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10066481 Hematological malignancy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) DK (Ongoing) ES (Ongoing) PL (Ongoing) IT (Ongoing) HU (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-003739-32 Sponsor Protocol Number: 1801 Start Date*: 2020-02-28
    Sponsor Name:Actuate Therapeutics Inc
    Full Title: Actuate 1801: Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, as a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematological Malignan...
    Medical condition: Refractory Hematologic Malignancies or Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066476 Haematological malignancy PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065147 Malignant solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002554-23 Sponsor Protocol Number: BGB-A317-290-LTE1 Start Date*: 2020-12-09
    Sponsor Name:BeiGene, Ltd.
    Full Title: An Open-Label, Multicenter, Long-term Extension Study of Tislelizumab-Containing Treatment and/or Pamiparib-Containing Treatment in Patients With Advanced Malignancies
    Medical condition: solid tumors and hematological malignancies
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065147 Malignant solid tumor LLT
    21.1 100000004864 10066481 Hematological malignancy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) IT (Ongoing) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-001284-23 Sponsor Protocol Number: XM22-ONC-305 Start Date*: 2013-12-10
    Sponsor Name:Merckle GmbH
    Full Title: A randomized, phase IIIB, open-label, two-arm, multicenter, comparatiVe study on efficacy and safety of lipegfilgrastim (Lonquex, TEVA) in comparison to pegfilgrastim (Neulasta®, Amgen) in elderly ...
    Medical condition: The study population includes patients with aggressive B cell Non-Hodgkin Lymphoma (NHL) planned to receive systemic anti-cancer therapy with at least 6 cycles of R-CHOP-21, according to local stan...
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10066481 Hematological malignancy LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) IT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Apr 28 22:17:03 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA